Kamada Announces New Data on its Glassia Drug Supporting its Diabetes ... Business Wire (press release) Based on the results, Kamada reports that its AAT protein is modulating the activity of type B lymphocytes and by that enables the avoidance of organ transplant rejection and raises the likelihood for the transplant success. “It seems that bacteria is ... |
